Skin cancer substantially contributes to the burden of skin disease in the US, with an average of approximately 6 million patients treated each year and annual treatment costs of $8.9 billion.1 Public health efforts to reduce or prevent skin cancer have focused on sun protection and UV awareness, but adherence to sunscreen recommendations is low.2 Dermatologists may treat precancerous actinic keratoses with spot cryotherapy or topical field treatments, but the adverse skin reactions may present a barrier to treatment or retreatment. Thus, the opportunity for an oral chemopreventive agent is an attractive one.